Drug intelligence / Profile preview

JW0104 + C2207

Development stage: Unknown
Lead developer: JW Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

JW0104 + C2207 is a combination of two investigational small molecule drugs developed by JW Pharmaceutical for potential use in cardiovascular and metabolic diseases. The combination has been evaluated in clinical trials to assess pharmacokinetic drug interactions and safety, particularly in healthy adults. Both drugs are orally administered, but their specific mechanisms of action have not been publicly disclosed[1][9]. The primary indications under investigation include dyslipidemias and hypertension, although the exact therapeutic targets remain unknown[1][2].

Beyond the preview

Go deeper on JW0104 + C2207.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JW0104 + C2207.

Explore the full profile